← All trials
NCT04716881
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2021
- Primary completion
- May 15, 2022
- Completion date
- Aug 15, 2022
- First posted
- Jan 20, 2021
- Last posted
- Sep 21, 2021
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Go Medical Industries Pty LtdLead sponsor
- ClinilabsCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- Columbia UniversityCollaborator
- Columbia UniversityOverall official - principal investigator
- Columbia UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.